384 related articles for article (PubMed ID: 31805888)
1. Remodeling of hepatic stellate cells orchestrated the stroma-derived oxaliplatin-resistance through CCN3 paracrine in hepatocellular carcinoma.
Liao X; Bu Y; Chang F; Jia F; Song G; Xiao X; Zhang M; Ning P; Jia Q
BMC Cancer; 2019 Dec; 19(1):1192. PubMed ID: 31805888
[TBL] [Abstract][Full Text] [Related]
2. Paracrine effects of CCN3 from non-cancerous hepatic cells increase signaling and progression of hepatocellular carcinoma.
Li W; Liao X; Ning P; Cao Y; Zhang M; Bu Y; Lv J; Jia Q
BMC Cancer; 2019 Apr; 19(1):395. PubMed ID: 31029128
[TBL] [Abstract][Full Text] [Related]
3. CCN3 is a therapeutic target relating enhanced stemness and coagulation in hepatocellular carcinoma.
Jia Q; Xue T; Zhang Q; Cheng W; Zhang C; Ma J; Bu Y; Yu S; Liu Q
Sci Rep; 2017 Oct; 7(1):13846. PubMed ID: 29061995
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo.
Garcia MG; Bayo J; Bolontrade MF; Sganga L; Malvicini M; Alaniz L; Aquino JB; Fiore E; Rizzo MM; Rodriguez A; Lorenti A; Andriani O; Podhajcer O; Mazzolini G
Mol Pharm; 2011 Oct; 8(5):1538-48. PubMed ID: 21770423
[TBL] [Abstract][Full Text] [Related]
5. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
6. Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids.
Song Y; Kim SH; Kim KM; Choi EK; Kim J; Seo HR
Sci Rep; 2016 Nov; 6():36750. PubMed ID: 27853186
[TBL] [Abstract][Full Text] [Related]
7. Hepatic stellate cells activated by acidic tumor microenvironment promote the metastasis of hepatocellular carcinoma via osteopontin.
Song J; Ge Z; Yang X; Luo Q; Wang C; You H; Ge T; Deng Y; Lin H; Cui Y; Chu W; Yao M; Zhang Z; Gu J; Fan J; Qin W
Cancer Lett; 2015 Jan; 356(2 Pt B):713-20. PubMed ID: 25449435
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts.
Zhou Y; Ren H; Dai B; Li J; Shang L; Huang J; Shi X
J Exp Clin Cancer Res; 2018 Dec; 37(1):324. PubMed ID: 30591064
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma.
Cho Y; Park MJ; Kim K; Park JY; Kim J; Kim W; Yoon JH
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940813
[TBL] [Abstract][Full Text] [Related]
10. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
11. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma.
Xie YX; Liao R; Pan L; Du CY
Immunol Lett; 2017 Aug; 188():116-123. PubMed ID: 28668554
[TBL] [Abstract][Full Text] [Related]
12. STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway.
Zhang R; Gao X; Zuo J; Hu B; Yang J; Zhao J; Chen J
Cancer Sci; 2020 Feb; 111(2):406-417. PubMed ID: 31785057
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production.
Myojin Y; Hikita H; Sugiyama M; Sasaki Y; Fukumoto K; Sakane S; Makino Y; Takemura N; Yamada R; Shigekawa M; Kodama T; Sakamori R; Kobayashi S; Tatsumi T; Suemizu H; Eguchi H; Kokudo N; Mizokami M; Takehara T
Gastroenterology; 2021 Apr; 160(5):1741-1754.e16. PubMed ID: 33346004
[TBL] [Abstract][Full Text] [Related]
14. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma.
Ji J; Eggert T; Budhu A; Forgues M; Takai A; Dang H; Ye Q; Lee JS; Kim JH; Greten TF; Wang XW
Hepatology; 2015 Aug; 62(2):481-95. PubMed ID: 25833323
[TBL] [Abstract][Full Text] [Related]
15. Cluster of differentiation 147 is a key molecule during hepatocellular carcinoma cell-hepatic stellate cell cross-talk in the rat liver.
Ma T; Wang Z; Yang Z; Chen J
Mol Med Rep; 2015 Jul; 12(1):111-8. PubMed ID: 25738354
[TBL] [Abstract][Full Text] [Related]
16. CCN1/Cyr61 enhances the function of hepatic stellate cells in promoting the progression of hepatocellular carcinoma.
Li ZQ; Wu WR; Zhao C; Zhao C; Zhang XL; Yang Z; Pan J; Si WK
Int J Mol Med; 2018 Mar; 41(3):1518-1528. PubMed ID: 29286082
[TBL] [Abstract][Full Text] [Related]
17. Extracellular vesicles-derived OncomiRs mediate communication between cancer cells and cancer-associated hepatic stellate cells in hepatocellular carcinoma microenvironment.
Li J; Yan Y; Ang L; Li X; Liu C; Sun B; Lin X; Peng Z; Zhang X; Zhang Q; Wu H; Zhao M; Su C
Carcinogenesis; 2020 Apr; 41(2):223-234. PubMed ID: 31140556
[TBL] [Abstract][Full Text] [Related]
18. Periostin involved in the activated hepatic stellate cells-induced progression of residual hepatocellular carcinoma after sublethal heat treatment: its role and potential for therapeutic inhibition.
Zhang R; Lin XH; Ma M; Chen J; Chen J; Gao DM; Cui JF; Chen RX
J Transl Med; 2018 Nov; 16(1):302. PubMed ID: 30400797
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma.
Seitz T; Freese K; Dietrich P; Thasler WE; Bosserhoff A; Hellerbrand C
Sci Rep; 2020 Mar; 10(1):4546. PubMed ID: 32161315
[TBL] [Abstract][Full Text] [Related]
20. CTGF Mediates Tumor-Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression.
Makino Y; Hikita H; Kodama T; Shigekawa M; Yamada R; Sakamori R; Eguchi H; Morii E; Yokoi H; Mukoyama M; Hiroshi S; Tatsumi T; Takehara T
Cancer Res; 2018 Sep; 78(17):4902-4914. PubMed ID: 29967264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
